Searched for: school:LISOM
Angioedema following Thrombolysis in Acute Ischemic Stroke: A Population-Based Cross-Sectional Study of 99,935 Patients
Uddin, Anaz; Huhulea, Ellen N; Jain, Ankita; Syed, Shoaib A; Lui, Aiden K; Clare, Kevin; Spirollari, Eris; Paul, Dennis; Sacknovitz, Ariel; Vazquez, Sima; Sasan, Charanpreet; Nguyen, Terry; Mammadli, Gular; Russo, Brittany; Medicherla, Chaitanya; Etienne, Mill; Al-Mufti, Fawaz
INTRODUCTION/BACKGROUND:Orolingual angioedema is a recognized adverse effect of thrombolytic treatment for acute ischemic stroke (AIS). Although it is generally mild with a relatively low incidence (1-5%), orolingual angioedema may trigger life-threatening airway occlusion necessitating rapid intubation. This population-based, retrospective study is the first to examine differences in complications, management, and outcomes of AIS in patients with and without thrombolysis-induced angioedema. METHODS:The National Inpatient Sample (NIS) was queried by International Classification of Disease Ninth and Tenth Revision diagnostic and procedural codes (ICD-9-CM/ICD-10-CM) to identify AIS patients treated with thrombolysis who experienced subsequent angioedema. Baseline characteristics, treatment, complications, and functional outcomes were analyzed through multivariate regression and compared through a propensity-score matching (PSM) analysis. RESULTS:We examined 99,935 patients diagnosed with AIS and administered thrombolytics between 2010 and 2019. AIS patients with thrombolytic-induced angioedema were younger (67.44 years vs. 69.32 years, p < 0.01), less likely to be white (53.83% vs. 66.48%, p < 0.01), and presented with higher acute stroke severity scores (0.69 vs. 0.63, p < 0.01) than non-angioedema AIS patients. Following PSM analysis, patients with angioedema had higher rates of tracheostomy (5.7% vs. 0.49%, p < 0.01) and lower rates of endovascular mechanical thrombectomy (4.72% vs. 9.63%, p < 0.01). Though patients who developed angioedema were observed to have longer length of stay (LOS) (7.34 days vs. 5.41 days, p < 0.01), they demonstrated similar rates of adverse complications, poor functional outcome (p = 0.25), and in-hospital mortality (p = 0.32) compared to their non-angioedema AIS counterparts. CONCLUSION/CONCLUSIONS:Although angioedema increased the likelihood of tracheostomy and prolonged hospitalization, outcomes were comparable to those of patients without this complication. These findings are hypothesis-generating and may help guide discussions with families when angioedema occurs, demonstrating that while the need for airway intervention is more likely, the overall prognosis remains reassuring. Future studies should further clarify acute management strategies and long-term outcomes in this patient population.
PMID: 41662303
ISSN: 1421-9786
CID: 6076253
A nationwide analysis of acute ischemic stroke in intravascular large B-cell lymphoma: the needle in a haystack
Subah, Galadu; Patel, Rohan; Sacknovitz, Ariel; Fortunato, Michael; Vazquez, Zachary; Hammouda, Yomna; Uddin, Anaz; Li, Austin; Lui, Aiden K; Chi, Sunny; Clare, Kevin; Aifuwa, Esewi; Al-Mufti, Jude; Russo, Brittany; Ali, Ahya; Al-Jehani, Hosam; Medicherla, Chaitanya; Parauda, Sarah C; Gandelman, Stephanie; Mayer, Stephan; Gandhi, Chirag; Al-Mufti, Fawaz
OBJECTIVE/UNASSIGNED:A significantly increased risk of cerebrovascular disease (CVD) is well documented among patients diagnosed with various malignancies. Cancer patients face nearly double the risk of acute ischemic stroke (AIS) compared to the general population. Intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma characterized by the proliferation of neoplastic lymphoma cells within the vasculature of organs. Occurring in <0.5 per 1,000,000 persons, it is exceptionally rare. This study investigates AIS occurrence in IVLBCL patients. METHODS/UNASSIGNED:The National Inpatient Sample (NIS) was queried from the period of 2010-2019 using the International Classification of Diseases (ICD) 9th and 10th edition codes to identify patients admitted for AIS either with or without IVLBCL. RESULTS/UNASSIGNED: < 0.05). CONCLUSION/UNASSIGNED:While limited by database constraints and IVLBCL's rarity, this study highlights the potential link between IVLBCL and AIS. These findings not only emphasize the importance of vigilance and preventive measures in managing the health of cancer patients but also suggest potential avenues for enhancing patient care and outcomes.
PMID: 40958081
ISSN: 1743-1328
CID: 6076252
Treatment and Outcomes for Acute Ischemic Stroke in Cardiomyopathy Patients With Heart Failure: A Retrospective Cross-Sectional Study
Kishore Jain, Aarti; Gozum, Nimrod; Wong, Serena; Nolan, Bridget E; Clare, Kevin M; Feldstein, Eric; Vazquez, Sima; Russo, Brittany; Thomas, Anish; Lui, Aiden; Pandit, Maya; Kaur, Gurmeen; Medicherla, Chaitanya; Gandhi, Chirag D; Al-Mufti, Fawaz
Cardiomyopathy (CM) is a common cause of heart failure (HF), and those with HF have up to a 3-fold increased risk of stroke. This study aims to examine the incidence of intravascular thrombolysis and endovascular thrombectomy and the functional outcomes in acute ischemic stroke (AIS) patients with CM and HF. International Classification of Diseases-10 codes were used to query the National Inpatient Sample database for patients with AIS and concurrent CM and HF from 2016 to 2019. Incidence of reperfusion therapy, medical complications, discharge disposition, length of hospital stay, and mortality between patients with and without CM and HF were compared using propensity score matching and multivariable logistic regression analysis. Of 2,939,160 patients identified with AIS, 80,915 (2.8%) had concomitant diagnoses of CM and HF. Patients in this population had more severe strokes (25.9% vs 19.6%, P < 0.001) and received endovascular thrombectomy at higher rates (8.8% vs 5.6%, P < 0.001) but equivalent rates of intravascular thrombolysis (3.0% vs 2.9%, P = 0.107). Additionally, CM/HF patients were more likely to experience inpatient death (6.6% vs 5.4%, P < 0.001). Despite this, those who survived were statistically more likely to have a favorable discharge disposition (45.7% vs 43.9%, P < 0.001). Although CM and HF patients are more likely to experience complications, prolonged length of stay, and inpatient death, those who survive have higher rates of favorable discharge disposition. These results suggest that stroke intervention is safe and efficacious in patients with CM and HF.
PMID: 42092332
ISSN: 1538-4683
CID: 6076254
NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study
Mohamed, A; Azmi, A; Kocak, M; Sonbol, M B; Konda, B; Dowlati, A; Nagel, C; Haider, M; Laderian, B; Asa, S L; Tirumani, S H; Garcia, J; Mahipal, A; Bajor, D; Chakrabarti, S; Selfridge, J E; Conces, M; Lumish, M; Hoehn, R S; Winter, J; Fu, P; Ammori, J; Hardacre, J; Henke, L E; Khan, H Y; Morgan, C; Raheem, D Abedal; Donohue, D; Fowler, P; Kaseb, A
Extrapulmonary neuroendocrine carcinomas (EP-NECs) are a heterogeneous group of rare tumors with poor clinical outcomes. These patients have limited treatment options after progressing on first-line platinum-based chemotherapy. Although dual immune checkpoint inhibitors (ICIs) with anti-CTLA-4 and anti-PD-1 blockade have significantly improved outcomes for several solid tumors, they demonstrated modest activity for EP-NECs with 9-26% response rates and low survival rates. Preliminary data demonstrated that NP-101 (Nigella sativa formulation) enhances T-cell infiltration and is synergistic with dual ICPIs in NECs' cellular models. This pilot study evaluated the tolerability and efficacy of NP-101 plus nivolumab and ipilimumab in patients with metastatic EP-NECs refractory to first-line platinum-based chemotherapy. This is a single-arm pilot study (NCTNCT05262556) in which patients with metastatic EP-NECs received NP-101 (oral capsules), 3,000 mg daily, plus ICPIs (intravenous nivolumab 3 mg/kg and ipilimumab 1 mg/kg) every 3 weeks for four cycles. Nonprogressors received NP-101 (3,000 mg daily), plus biweekly maintenance of nivolumab (240 mg), and then completed 24 weeks of treatment. Treatment-related adverse events (TR-AEs) were characterized according to CTCAE v4.03. The response rate was estimated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. The Kaplan-Meir method was used to estimate median PFS and OS. Twelve patients received ≥1 dose of NP-101 and nivolumab plus ipilimumab. There were no dose-limiting toxicities (DLTs). Grade 1/2 TR-AEs occurred in 100% (12/12) of patients. The most common G1/2 TR-AEs included the following: fatigue (75%), nausea (41.7%), pruritus (41.7%), muscle weakness (33.3%), vomiting (25%), rash (25%), and abdominal pain (25%). Eight patients (66%) experienced grade 3/4 TR-AEs, including rash (33.3%), nausea (16.7%), vomiting (16.7%), and transaminitis (16.7%). No treatment-related grade 5 toxicities or deaths were recorded. The objective response rate was 41.7% (2/12 (16%) complete response (CR) + 3/12 (25%) partial response (PR); 95% CI: 15.2-72.3%) for all patients and 50% (2/8 CR + 2/8 PR, 95% CI: 0.16-0.84) for patients with NEC of gastrointestinal origin. The median duration of response was 7.5 months. As for the median progression-free survival, it was 5.7 months, and the median overall survival (OS) was 10.5 months with a median follow-up of 10.4 months. The combination of NP-101 plus dual ICPIs (nivolumab and ipilimumab) was safe and well tolerated with preliminary evidence of antineoplastic activity. Currently, a randomized phase II clinical trial evaluating the combination is under development.
PMID: 42012995
ISSN: 1479-6821
CID: 6076226
Spontaneous Regression of Colon Adenocarcinoma: A Case for Reconsideration [Case Report]
Dehghani, S Sharareh; Kaul, Arunima; Hertan, Hilary; Laderian, Bahar; Andreade, Christopher
PMID: 41412912
ISSN: 1938-0674
CID: 6076227
Contemporary clinical characteristics, management strategies, and outcomes of fluoropyrimidine-induced angina - A descriptive study
Zalaquett, Ziad; Chedid El Helou, Michel; Laderian, Bahar; Shukla, Neehal; Griffin, Brian; Moudgil, Rohit; Collier, Patrick
Fluoropyrimidines can cause angina-like chest pain, often attributed to coronary vasospasm. We retrospectively reviewed 137 patients at Cleveland Clinic (2017-2023) who developed chest pain during 5-fluorouracil or capecitabine treatments. Most events occurred early (75 % within four cycles). Troponin elevation (42 %) and ischemic electrocardiographic changes (43 %) were common, yet most catheterized patients had no obstructive coronary disease. Rechallenge was attempted in 64 % of patients, with recurrence in 36 %, and no predictors of recurrence were identified. Fluoropyrimidine-associated angina is therefore frequent, with high rates of recurrence, and unpredictable, highlighting the need for standardized diagnostic and management strategies.
PMID: 41319731
ISSN: 1876-4738
CID: 6076228
Corrigendum to Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations Transplant Cell Ther. 2025 Sep;31(9):680-692. doi: 10.1016/j.jtct.2025.05.019. Epub 2025 May 24
Mehta, Rohtesh S; Schmidt, Gabrielle; Williams, Kirsten; Patel, Shyam A; Schetelig, Johannes; Savani, Bipin; Askar, Medhat; Petersdorf, Effie; Ringden, Olle; Kanakry, Christopher G; Kanakry, Jennifer A; Stefanski, Heather; Arrieta-Bolaños, Esteban; Betts, Brian; Benjamin, Cara; Gadalla, Shahinaz; Wang, Tao; Saultz, Jennifer; Spellman, Stephen; Jurdi, Najla El; Bolon, Yung-Tsi; Lee, Stephanie J
PMID: 42956832
ISSN: 2666-6367
CID: 6076197
Translating fibroblast heterogeneity into prognosis and immune stratification in pancreatic cancer using machine learning [Comment]
Liu, Yao-Zhong; Liu, Yongjun; Zhang, Xiaofei
PMID: 42996607
ISSN: 2078-6891
CID: 6075706
WGO AI Guidelines: Manuscript 3 AI on the Horizon-Part I Review on AI in Upper GI and Biliopancreatic Endoscopy
Saraiva, Miguel M; da Costa, António M M P; de Carvalho, Matheus F; Espino, Alberto; Sethi, Amrita; Zatarain, Ana; Metz, Andrew; Riquelme, Arnoldo; Kaffes, Arthur; Almuhaidb, Aymen; Agudo, Belén; González, Carlos A; Kim, Grace E; Vargas, Jose I; Kok, Khoon S; Lovat, Laurence; Sabbagh, Luis C; Lera, Marcos; González, Mariano; Villarroel, Mariano; Adams, Mason; Keegan, Mathew; Saxena, Payal; Gonda, Tamas; Siddiqui, Uzma D; Aggarwal, Vipul; Marlicz, Wojciech; Canavesi, Adrian; Silva, Adriana F; Pérez-Gonzalez, Ana; Velasquez, Andrea; Taullard, Andrés; Bercier, Baret; Dickson, Chance; Ejima, Gustavo; Fortes, Erika B; Filho, Hiram M N; González, Ivan; Mota, Joana; Sasso, João G R J; de Oliveira, Luiza B; Almeida, Maria J; Boghossian, Mateus B; Alrossais, Naif; Mingos, Nicholas; González, Nicolas; Cardoso, Pedro; de Moura, Eduardo G H; Widmer, Jessica; Macedo, Guilherme; ,
Artificial intelligence is increasingly transforming gastrointestinal endoscopy, particularly in endoscopic ultrasound (EUS), biliary disease, and upper gastrointestinal (GI) endoscopy. EUS plays a key role in evaluating subepithelial lesions (SELs) and solid and cystic pancreatic neoplasms, incorporating techniques such as elastography and contrast enhancement. Nonetheless, its diagnostic performance remains strongly operator-dependent, with notable interobserver variability and only moderate accuracy even among experienced endosonographers. Computational models applied to EUS images and videos have shown encouraging results in lesion detection, characterization, and risk stratification, in some cases reaching or exceeding expert-level performance. However, most available data are retrospective and derived from single-center studies. Cholangiocarcinoma continues to be associated with poor outcomes, largely due to delayed diagnosis and the difficulty of distinguishing malignant from benign biliary strictures. Although advances in cholangioscopy, imaging, and tissue acquisition have improved diagnostic yield, indeterminate strictures remain frequent. The incorporation of artificial intelligence into imaging analysis, radiologic assessment, and tissue evaluation may improve diagnostic precision, decrease unnecessary procedures, and provide real-time decision support. In upper GI endoscopy, detection and characterization of esophageal and gastric neoplasia remain inconsistent in daily practice and are highly dependent on operator expertise. Emerging systems can enhance lesion recognition, reduce variability among observers, and assist real-time assessment. Overall, these technologies represent a promising adjunct across endoscopic modalities, although prospective multicenter validation and real-time clinical integration are still required for widespread adoption.
PMID: 43000639
ISSN: 1539-2031
CID: 6075715
Safety and Efficacy of Low-Dose Ketamine Infusion for Pain Management after Cardiac Surgery:A Single Center Pre-Post Analysis
Hall, James; Yi, Hyogun; Weihs, Jenna; Rajan, Anand; Weinberger, Andrew; Sharma, Vivek; Yoo, Noah
OBJECTIVES/OBJECTIVE:To evaluate whether the addition of continuous low-dose ketamine infusion to an enhanced recovery after surgery (ERAS) protocol reduces postoperative opioid consumption and improves pain control after cardiac surgery. DESIGN/METHODS:Single-center, retrospective, before-and-after cohort study with propensity score matching. SETTING/METHODS:University-affiliated tertiary care hospital cardiothoracic intensive care unit. PARTICIPANTS/METHODS:Adult patients undergoing cardiac surgery and admitted postoperatively to the cardiothoracic intensive care unit between June 2023 and January 2025. INTERVENTIONS/METHODS:Patients managed under an ERAS protocol without ketamine (control) were compared with patients managed under ERAS plus a continuous postoperative low-dose ketamine infusion (0.1-0.3 mg/kg/h). MEASUREMENTS AND MAIN RESULTS/RESULTS:The primary outcome was opioid consumption in morphine milligram equivalents (MME) from postoperative day (POD) 0-2. Secondary outcomes included pain scores, time to first analgesic, recovery metrics, length of stay, and adverse events. Of 548 screened patients, 244 were included after propensity matching (122 ketamine, 122 control). Ketamine was associated with lower cumulative opioid use through POD2 (30 vs 52.5 MME; p = 0.003), with reductions on POD0 and POD1. Time to first analgesic was longer (7.4 vs 4.5 h; p < 0.001), and maximum pain scores were lower across the first 48 hours (all p < 0.05). Intensive care unit length of stay was modestly longer, while hospital length of stay was shorter in the ketamine group. No hallucinations were observed, delirium rates were low, and urinary retention was significantly reduced (9.8% vs 34%; p < 0.001). CONCLUSION/CONCLUSIONS:Within an ERAS pathway after cardiac surgery, low-dose ketamine infusion was associated with reduced opioid use and improved early postoperative pain control without increased central nervous system adverse events, supporting its role as a safe adjunct in postoperative analgesia.
PMID: 43026044
ISSN: 1532-8422
CID: 6075937